Skip Navigation


Annals of Oncology Advance Access originally published online on February 27, 2008
Annals of Oncology 2008 19(6):1053-1059; doi:10.1093/annonc/mdn006
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 8 iss...
Right arrow Supplementary Data
Right arrow All Versions of this Article:
19/6/1053    most recent
mdn006v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weiss, G. J.
Right arrow Articles by Franklin, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiss, G. J.
Right arrow Articles by Franklin, W. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

lung cancer

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines

G. J. Weiss1,*, L. T. Bemis2, E. Nakajima3, M. Sugita4, D. K. Birks2, W. A. Robinson2, M. Varella-Garcia2, P. A. Bunn, Jr2, J. Haney4, B. A. Helfrich2, H. Kato3, F. R. Hirsch2 and W. A. Franklin4

1 TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, AZ, USA
2 Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA
3 Department of Surgery, Tokyo Medical University, Tokyo, Japan
4 Department of Pathology, University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA

* Correspondence to: G. J. Weiss, MD, TGen Clinical Research Services at Scottsdale Healthcare, 10510 N 92nd Street, Suite 200, Scottsdale, AZ 85258, USA. Tel: +1-480-323-1350; Fax: +1-480-323-1359; E-mail: gweiss{at}tgen.org

Background: Allelic loss in chromosome 3p is one of the most frequent and earliest genetic events in lung carcinogenesis. We investigated if the loss of microRNA-128b, a microRNA located on chromosome 3p and a putative regulator of epidermal growth factor receptor (EGFR), correlated with response to targeted EGFR inhibition. Loss of microRNA-128b would be equivalent to losing a tumor suppressor gene because it would allow increased expression of EGFR.

Patients and Methods: We initially showed that microRNA-128b is a regulator of EGFR in non-small-cell lung cancer (NSCLC) cell lines. We tested microRNA-128b expression levels by quantitative RT–PCR, genomic copy number by quantitative PCR, and mutations in the mature microRNA-128b by sequencing. We determined whether microRNA-128b loss of heterozygosity (LOH) in 58 NSCLC patient samples correlated with response to gefitinib and evaluated EGFR expression and mutation status.

Results: We determined that microRNA-128b directly regulates EGFR. MicroRNA-128b LOH was frequent in tumor samples and correlated significantly with clinical response and survival following gefitinib. EGFR expression and mutation status did not correlate with survival outcome.

Conclusion: Identifying microRNA regulators of oncogenes could have far-reaching implications for lung cancer patients including improving patient selection for targeted agents, development of novel therapeutics, or development as early biomarkers of disease.

Key words: epidermal growth factor receptor, gefitinib, microRNA, non-small-cell lung cancer

Received for publication November 7, 2007. Revision received December 19, 2007. Accepted for publication January 2, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
E. Gallardo, A. Navarro, N. Vinolas, R. M. Marrades, T. Diaz, B. Gel, A. Quera, E. Bandres, J. Garcia-Foncillas, J. Ramirez, et al.
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
Carcinogenesis, November 1, 2009; 30(11): 1903 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. D. Adams, D. M. Cowee, and B. A. White
The Role of miR-206 in the Epidermal Growth Factor (EGF) Induced Repression of Estrogen Receptor-{alpha} (ER{alpha}) Signaling and a Luminal Phenotype in MCF-7 Breast Cancer Cells
Mol. Endocrinol., August 1, 2009; 23(8): 1215 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Genomics ProteomicsHome page
N. VALERI, C. M. CROCE, and M. FABBRI
Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer
Cancer Genomics Proteomics, July 1, 2009; 6(4): 195 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. L. Bartels and G. J. Tsongalis
MicroRNAs: Novel Biomarkers for Human Cancer
Clin. Chem., April 1, 2009; 55(4): 623 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
J. E. Duex and A. Sorkin
RNA Interference Screen Identifies Usp18 as a Regulator of Epidermal Growth Factor Receptor Synthesis
Mol. Biol. Cell, March 15, 2009; 20(6): 1833 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. P. Nana-Sinkam, M. G. Hunter, G. J. Nuovo, T. D. Schmittgen, R. Gelinas, D. Galas, and C. B. Marsh
Integrating the MicroRNome into the Study of Lung Disease
Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 4 - 10.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. M. Nelson and G. J. Weiss
MicroRNAs and cancer: past, present, and potential future
Mol. Cancer Ther., December 1, 2008; 7(12): 3655 - 3660.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Godlewski, M. O. Nowicki, A. Bronisz, S. Williams, A. Otsuki, G. Nuovo, A. RayChaudhury, H. B. Newton, E. A. Chiocca, and S. Lawler
Targeting of the Bmi-1 Oncogene/Stem Cell Renewal Factor by MicroRNA-128 Inhibits Glioma Proliferation and Self-Renewal
Cancer Res., November 15, 2008; 68(22): 9125 - 9130.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. S. Herbst, J. V. Heymach, and S. M. Lippman
Lung Cancer
N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.